Martin Shkreli

A high-conviction bearish opportunity is identified in Inmune Bio (INMB), with a prediction that the stock could fall 90% following its upcoming clinical data release. This thesis is based on a recent financing deal where INMB sold shares at a massive discount, signaling management's lack of confidence in their own data. Conversely, Sarepta Therapeutics (SRPT) is presented as a major long-term investment holding due to its recovery potential, despite recent underperformance. Other stocks with a strong bearish outlook include Anavex (AVXL), Capricor (CAPR), and IonQ (IONQ), which are viewed as potential short-selling candidates. For investors seeking stability, Intercontinental Exchange (ICE) is highlighted as a high-quality company with a very profitable business model.

A high-conviction short opportunity is identified in InMune Bio (INMB), with expectations of a 90% stock drop following its upcoming Alzheimer's trial data release. Conversely, Sarepta Therapeutics (SRPT) is a strong long-term buy, with its limb-girdle muscular dystrophy (LGMD) gene therapy pipeline viewed as a major, underappreciated catalyst. The analyst is also actively shorting speculative stocks BigBear.ai (BBAI), IonQ (IONQ), and D-Wave Quantum (QBTS), believing they are fundamentally flawed. For a potential long idea, Madrigal Pharmaceuticals (MDGL) was mentioned favorably and is worth further research. These event-driven biotech trades carry significant risk and investors should proceed with caution.

A high-conviction bearish trade is on InMune Bio (INMB) ahead of its imminent Alzheimer's data, with puts at strikes like $5 or $2.50 being a way to position for an expected trial failure. Amgen (AMGN) is a contrarian buy opportunity, as the market over